Floatz logo

Anti-Egfr-Bispecific Antibody Armed Activated T-Cells

Glioblastoma

University of VirginiaCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

353 Active assets in the Glioblastoma cohort.

Asset / SponsorPhaseRating
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB
CARMUSTINE
Leland Metheny
Phase 3BB
Cintredekin Besudotox
INSYS Therapeutics Inc
Phase 3BB

View all 50 →

Same molecule, other indications

Anti-Egfr-Bispecific Antibody Armed Activated T-Cells is also rated in:

malignant pancreatic neoplasmDormant
CC
Indicative ·
41 / 100
View asset →
pancreatic adenocarcinomaDormant
C
Indicative ·
39 / 100
View asset →
pancreatic neoplasmDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →